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Case Reportscardiopulmonary bypass, with an excellent size match
with the recipient.
Postoperative bronchoscopy showed moderate mucosal
inflammation with intact anastomoses. The recipient
was extubated after 5 days, transferred to the ward on day
10 and discharged on day 22. He continues to do well
8 months postoperatively, with satisfactory chest radiog-
raphy, blood gas evaluation, and spirometry results.
DISCUSSION
Despite the shortage of organ donors, only 17% of donor
lungs in the United States and 15% in the United Kingdom
are used for transplantation, with ‘‘poor function’’ cited as
the causeof 60%ofdonor organ rejections inNorthAmerica.1
Organ retrieval often involves thoracic and abdominal
teams sharing operating space and working ‘‘against the
clock.’’ Nevertheless, errors may have untoward conse-
quences, such as the accidental delivery of pulmonoplegia
at high pressure in this report. It is well established that
high flow induces pulmonary vasculopathy as a result of
high pressure and high shear stress with time,3 and flushing
pressures lower than 20 mm Hg have been advocated for
lung preservation.4 Assessment of lungs in a multiorgan
donor is limited, however, by the necessity to maintain
sufficient circulation and oxygen delivery to the other organ
systems. In addition, there are no specific data on whether
lungs subjected to excessive perfusion pressure sustain
significant vascular barotrauma and whether such lungs can
be successfully transplanted. The influence of high-pressure
pulmonoplegia onprimary graft dysfunction is alsounknown,
and the consequent risk oforgan failure in the recipient cannot
be quantified. Because of the scarcity of available organs and
the fact that all preretrieval parameters were excellent, we
decided to evaluate the lungs with EVLP. In this case,
EVLP assessment of lung viability was satisfactory despite
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The Journal of Thoracic and Cathe lungs were successfully transplanted. Possible explana-
tions for the successful outcome include (1) inaccurate
monitoring, with a low actual flushing pressure (unlikely);
(2) incision of the left atrial appendage facilitates
unobstructed drainage of perfusate, limiting the effect of hy-
pertension in the pulmonary vascular bed; (3) the physiologic
insult of very brief high flushing pressures is minimal; and
(4) EVLP mitigated the insult and optimized the lungs for
transplantation. EVLP can cost roughly £1500 to £2000
onward (costs may vary by center and country); however,
there is some evidence that that lungs initially rejected for
donation because of impaired function can be improved
during EVLP and eventually transplanted without compro-
mising early clinical results.5
CONCLUSIONS
High-pressure pulmonoplegia may not adversely
impact donor lungs sufficiently to preclude transplantation.
Our patient continues to do well 8 months postoperatively,
pending longer-term follow-up. EVLP may possibly
help to evaluate the transplant potential of donor lungs in
doubtful cases.
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J Thorac Cardiovasc Surg. 2012;144:1222-8.Cardiac allograft failure: Retransplant or long-term ventricular
assist device?
Tomohiro Saito, MD, Nicola Hiemann, MD, PhD, Thomas Krabatsch, MD, PhD,
Evgenij Potapov, MD, PhD, and Roland Hetzer, MD, PhD, Berlin, GermanyIn determining treatment for cardiac allograft failure, one
consideration is that outcomes after cardiac retransplants
have been reported to be inferior to those observed after
primary transplants.1 In addition, the ethical dimension of
the issue makes it difficult to reach a complete consensus.
We report implantation of a left ventricular assist device
for long-term support in a patient with cardiac allograft
failure caused by coronary allograft vasculopathy.rdiovascular Surgery c Volume 147, Number 3 e29
Case ReportsCLINICAL SUMMARY
A 37-year-old man with viral cardiomyopathy caused by
parvovirus B19 infection underwent heart transplant in
June 2008. The posttransplant course was uncomplicated.
Acute rejection was excluded in regular echocardiographic
studies; however, coronary allograft vasculopathy was
diagnosed on coronary angiography 1 year after heart
transplantation. In October 2012, the patient was seen in
New York Heart Association functional class III with
general fatigue and cough. He had independently
stopped taking the immunosuppressive agent 7 days
earlier. Echocardiography showed a left ventricular
ejection fraction of 35% and an end-diastolic diameter of
52 mm with severe diastolic dysfunction. Despite
low-grade cellular rejection (International Society for
Heart and Lung Transplantation grade 1B) and lack
of evidence of antibody-mediated rejection in the
endomyocardial biopsy, antithymocyte globulin, pulsed
corticosteroids, and immunoglobulin were intensively
administered, and plasmapheresis was performed during
the following 3 months because of the severity of the
echocardiographic findings combined with positive
donor-specific anti-HLA class II. After conventional
antirejection therapy failed, rituximab and bortezomib
were given; however, the patient could not be completely
weaned from inotropic support. The right ventricle was
not dilated and had a moderately impaired ejection fraction
of 40%. Tricuspid regurgitation was trivial.
After intensive discussion, our ethics and transplantation
committees ruled against the possibility of the patient
receiving a second heart transplant.
In April 2013, urgent left ventricular assist device
implantation was performed with cardiopulmonary bypass
through the groin vessels. The heart was approached
through a left lateral thoracotomy in the sixth intercostal
space. A HeartWare HVAD (HeartWare International, Inc,
Framingham, Mass) was implanted by a method described
previously2 with outflow graft connection to the descending
aorta. The postoperative course was uneventful, with stable
right ventricular function. The patient was discharged
home on postoperative day 46. Six months have passed
since the operation, and the patient is doing well at
home. He continues his immunosuppressive regimen
and receives anticoagulation according to our institutional
protocol.3e30 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
The decline in organ donations is a matter of social and
political concern. In the past 2 decades, various approaches
involving new legislation designed to increase the rate of
organ donation have been adopted; however, heart donation
has not notably increased.4 In this era of organ shortage, a
noncompliant patient would naturally be removed from
consideration for cardiac retransplant, and a chance for
survival and later relisting should be granted only after
reeducation has been successfully accomplished. On the
other hand, mechanical circulatory support intended as a
bridge to cardiac retransplant has been reported to resolve
hemodynamic instability related posttransplant allograft
failure, although it does not always contribute to a significant
improvement in clinical outcome after cardiac retransplant.5
Under these circumstances, VAD implantation as long-term
therapy rather than cardiac retransplant seems to be an
acceptable option for a limited group of patients who are
not willing to undergo a second heart transplant or are not
adherent to their medication regimen, although concerns
about anticoagulation and risk of infection remain.
Because of the advances being made in ventricular assist
device technology and the increasing durability of these
devices, it may not be long before ventricular assist devices
are implanted on a regular basis as destination therapy
rather than undertaking cardiac retransplant. We hope to
follow up our patient carefully to evaluate the validity of
our decision.
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